Heart-failure therapy update outlining trial progress and forthcoming development steps. Useful for readers tracking cardiovascular biotech momentum.
Key Takeaways
- APEX Phase 2 trial of TX45 in PH-HFpEF completed enrollment
- Randomized double-blind placebo-controlled study spans 24 weeks
- Trial enrolled 191 patients across 14 countries with 72% having PVR over 3 Wood units